Objectives: Various utility measures have been used to assess preference-based quality of life of patients with end-stage renal disease (ESRD). The purposes of this study were to summarize the literature on utilities of hemodialysis (HD), peritoneal dialysis (PD), and renal transplantation (RTx) patients, to compare utilities between these patient groups, and to obtain estimates for quality-of-life adjustment in economic analyses. Methods: We searched the English literature for studies that reported visual analog scale (VAS), time trade-off (TTO), standard gamble (SG), EuroQol-5D (EQ-5D), and health utilities index (HUI) values of ESRD patients. We extracted patient characteristics and utilities and calculated mean utilities and 95% confidence intervals (CIs) for categories defined by utility measure and treatment modality using randomeffects models. Results: We identified 27 articles that met the inclusion criteria. VAS articles were too heterogeneous to summarize quantitatively and we found only one study reporting HUI values. Thus, we summarized utilities from TTO, SG, and EQ-5D studies. Mean TTO and EQ-5D-index values were lower for dialysis compared to RTx patients, though not statistically significant for TTO values (TTO values: HD 0.61, 95% CI 0.54-0.68; PD 0.73, 95% CI 0.61-0.85; RTx 0.78, 95% CI 0.63-0.93; EQ-5D-index values: HD 0.56, 95% CI 0.49-0.62; PD 0.58, 95% CI 0.50-0.67; RTx 0.81, 95% CI 0.72-0.90). Mean HD versus PD associated TTO, EQ-5D-index and EQ-VAS values were not statistically significantly different. Conclusion: RTx patients tended to have a higher utility than dialysis patients. Among HD and PD patients, there were no statistically significant differences in utility.
Introduction
Health-related quality of life is becoming increasingly important as an outcome measure, especially in chronic diseases. It can be assessed with both general and disease-specific instruments. General instruments allow for comparisons of quality of life associated with different diseases. Many methods are currently available, and two types can be distinguished: health-profile measures and preference-based methods. Healthprofile measures assess health status on a number of domains, such as physical, emotional, or social impairments. An example of such a measure is the Medical Outcomes Study Short Form 36-Item Health Survey (SF-36). Preference-based methods assign a singleindex value to health-related quality of life. This value is expressed on a ratio scale and length of life is used as the metric for measuring the subject's preference for the quality of life in a given health state. Thus, quality of life is expressed in a quantitative measure of the strength of a person's preference for an outcome, also defined as a person's utility associated with the outcome. Examples include time trade-off (TTO) and standard gamble (SG) methods. Some health-profile measures allow for the calculation of a utility, using a tariff or set of preference weights. Such tariffs have been estimated by deriving general population utilities for all possible health states that may result from a health-profile method [1] . The valuations of those health states have been estimated using preferencebased methods. Utilities can be used in economic evaluations to adjust expected life-years for quality of life [1] .
End-stage renal disease (ESRD) is an example of a chronic disease for which quality of life is an important outcome measure. First, patients with ESRD generally have a diminished quality of life compared to the general population. Second, it has been shown that quality of life is a predictor of future morbidity and mortality for this patient population [2] [3] [4] [5] . ESRD entails the need for renal replacement therapy (RRT). Differences in quality of life associated with the alternative forms of RRT have been reported in the literature. When assessing studies using preference-based methods, renal transplantation (RTx) is associated with a higher quality of life than either hemodialysis (HD) or peritoneal dialysis (PD) [6] [7] [8] [9] . Nevertheless, other authors suggested that this might be due to preexisting different characteristics of patients selected for the alternative forms of RRT, such as age, sex, ethnicity, primary renal disease, and comorbidity [10] . Studies comparing the utilities of HD and PD patients remain controversial. Some studies show a higher quality of life for PD patients as compared to HD patients [8, 11] , whereas others found similar utilities for PD and HD patients [6, [12] [13] [14] [15] .
To adjust for quality of life in economic analyses in ESRD patients, summary estimates from metaanalyses would be helpful. The systematic review and meta-analysis we performed previously on healthrelated quality of life of these patients only included studies using the SF-36 [16] , a health-profile measure that cannot be used to adjust for quality of life in economic studies. Thus, the aims of the present study were to review and summarize the literature on preference-based quality of life of patients on RRT, to obtain mean utilities that can be used to adjust life expectancy in cost-effectiveness analyses, and to compare mean utilities of HD, PD, and RTx patients.
Methods

Study Retrieval
An English literature search was performed using Medline and PsycLIT. All articles from peer-reviewed journals, published before September 2006, were considered for inclusion. Additional studies were identified through the bibliographies of the articles that were found through this search. Studies were included if they met the following criteria: 1) they reported absolute utilities using the visual analog scale (VAS), TTO, or SG method or utilities derived from the EuroQol-5D (EQ-5D) or health utilities index (HUI) questionnaires; 2) they included at least one of the forms of RRT specified as HD, PD, or RTx; 3) data were collected prospectively; and 4) the sample size was at least 10 patients per treatment group. Articles were excluded if the data were provided by proxies. We also excluded studies on quality of life of combined pancreas-kidney transplant recipients. Of articles with similar or overlapping researchers or articles from the same center, we contacted the authors for additional information and if this was not possible, evaluated their independence by determining when, where, and how many subjects were included. If more than one published article reported data from the same subjects, the most recent was selected, unless its sample was smaller or less information on covariates was reported.
Utility Measures
The VAS is usually a 100 mm scale, ranging from 0 to 100, on which the respondent has to mark his valuation of his health status. The rating scale (RS) is the analogous question using a verbal rating on a scale from, for example, 0 to 100. It can be anchored in different ways: 0 can reflect the lowest possible quality of life, worst possible health status, or death, while 100 can reflect the highest possible quality of life, normal or perfect health.
The TTO approach was originally developed by Torrance et al. [17] and tested with respect to reliability and validity in ESRD patients by Churchill et al. [6] . It involves asking a patient to think about his kidney disease for the past 2 to 3 weeks and then choose between two hypothetical options: either remaining in his current health state for the patientspecific life expectancy or to trade off a number of years to live in full health. The number of years to be traded off is varied between 0 and the total life expectancy and the question is iterated until the patient is indifferent between the two options. The utility is then calculated by dividing the number of years that the patient would not be willing to trade by the total life expectancy at the point of indifference.
The SG method, derived from expected utility theory, requires the respondent to make a decision between either staying in his current health state or undergoing a hypothetical therapy [18] . This therapy has two possible outcomes: 1) there is a chance of immediate death; 2) if the patient survives he will be cured and will live in full health. The chance of death associated with this hypothetical therapy is varied in an iterative manner until the patient is indifferent between staying in his current health state and undergoing the hypothetical therapy. The utility is calculated as one minus the probability of death at the point of indifference.
The EQ-5D is a generic multiattribute utility that was developed by the EuroQol group [19] . It is selfadministered and comprises two parts. The first part, the EQ-5D profile, consists of five items: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with three levels of functioning: no problem, some problems, and extreme problems. Tariffs from several countries are available to compute a utility, the EQ-5D-index value, from an EQ-5D profile combination. The tariff based on the UK population sample values is most commonly used [20] . The second part of the questionnaire is the EQ-VAS, rating health from 0 (worst imaginable health state) to 100 (best imaginable health state).
The HUI is a multiattribute utility that describes almost one million health states, classified on different domains [21] . The most recent version is the HUI3, which classifies a health state on eight domains: ambulation, dexterity, cognition, emotion, pain and discomfort, vision, hearing, and speech. For the health states, utilities have been derived from a reference population using a combination of SG and RS values. This derivation was accomplished, using a multiattribute model which assumes that choices in which one domain or attribute is varied do not depend on the level of another domain. Preferences for a certain number of states were elicited and the utilities for the other states were derived using this model.
Data Extraction
A standardized data sheet was used to collect the data from the studies. Data were independently extracted by two readers (YSL, JLB) and discrepancies were resolved by discussion. Readers were not blinded to information about the authors, author affiliation, and journal name, because this has been shown to be unnecessary [22] . The extracted study characteristics included publication year, country and center of authors and patients, number of patients included, demographic and clinical patient characteristics and utilities. If discrepancies in numbers existed between text and tables, we extracted the number reported in the table. If utilities had to be read from a graph, we rounded off to the nearest 0.01 point on a 0-1 point scale.
From studies assessing quality of life after RTx at multiple time points, we extracted the utility at the time point closest to 12 months after transplantation, because this reliably reflects quality of life of RTx patients. From studies evaluating interventions, we extracted the utility at the baseline time-point to minimize the effect of the intervention on the mean qualityof-life estimate. If treatment groups were split up according to covariates, we preferred to use data of the total group, if reported. If total group data were not available, however, we included the groups as separate entries into the meta-analysis.
Data Synthesis and Analysis
We categorized the data according to both utility measure and treatment modality (HD, PD, and RTx). Per category, we assessed the number of studies, patient groups, and patients. We analyzed the data quantitatively for categories comprising at least three patient groups for which a mean utility was reported. If the standard deviation (SD) was not reported, we imputed the mean SD of the category. To be able to assess differences in patient characteristics, we also intended to summarize patient and clinical characteristics. As only age and sex were reported in most studies, we had to restrict our analyses to these variables; those studies not reporting age and sex were left out of the calculation of mean age and sex. For studies reporting only the mean but not a SD, the mean SD from the other studies was imputed. Quantitative analyses of the variables utility, age, and sex were thus performed. We tested for between-study homogeneity of the variables within each category, using the Q-statistic to provide descriptive information of between-study variation [23] . Because the tests for homogeneity have a low power, the acceptance of the null-hypothesis of homogeneity provides no firm evidence of the absence of between-study variation [23] . Therefore, we used random-effects models to calculate pooled weighted means and 95% confidence intervals (CIs) for all variables, also per category defined by utility measure and treatment modality. Randomeffects models weigh the outcomes of the study according to the within-study as well as the between-study variance [23] . In order to perform the analyses in the SAS 8.02 statistical program (SAS Institute Inc., Cary, NC, USA), we transformed the sex variable (proportion male) onto a logit-scale, assuming linearity of the logit. We tested for statistically significant differences between HD, PD, and RTx groups, using Student's t-tests. In addition, we compared mean age and sex among the treatment groups.
Results
Our search identified 127 studies, of which we excluded 68 on the basis of the abstract and 32 on the basis of the full text. Reasons for exclusion are depicted in Figure 1 . Exclusion of these studies ensured included studies to be of good quality. The remaining 27 studies that we included in our meta-analysis were of at least level 2b evidence according to the Oxford Center for Evidence-Based Medicine classification [24] . Quality of life was assessed with a single measure in most studies: three studies used a VAS [11, 25, 26] , eight studies the TTO [7, 14, [27] [28] [29] [30] [31] [32] , one study the SG [33] , and nine studies the EQ-5D [8, 9, 13, 15, [34] [35] [36] [37] [38] . In addition, there were six studies that used several utility measures: one used a VAS, the TTO, and SG [39] ; two used the TTO, SG, and EQ-5D [12, 40] ; one used a VAS and the TTO [6] ; one used the TTO and SG [41] ; and one used the TTO and HUI3 [42] . Tables 1-5 show, per category defined by utility measure and treatment modality, the patient groups (sample size, mean age, proportion males, and mean and SD of utilities) that were included from these studies.
For several categories, quantitative analyses were not performed. First of all, the groups in the VAS/HD category (Table 1) were reported in four articles, of which one article scaled VAS from worst possible to best possible health, one from death to perfect health, one from lowest to highest quality of life, and one did not report the anchors. As scaling varied so much, metaanalysis was considered not to be meaningful in this category. The HD group for which VAS was scaled from worst to best possible health was added to the analysis of the EQ-VAS values. Furthermore, there were not enough groups to calculate means for the categories VAS/PD, VAS/RTx, SG/PD, SG/RTx, and EQ-VAS/ RTx. Lastly, there was only one patient group for which a HUI value was reported (Table 5) . Thus, metaanalyses were performed for TTO utilities (HD, PD, and RTx patients), SG utilities (HD patients), EQ-5D-index utilities (HD, PD and RTx patients), and EQ-VAS utilities (HD and PD patients). Mean age and sex were also computed for these categories, except for the TTO/ RTx category, because not enough data were available.
Tests for homogeneity were statistically significant for the utility, age, and sex variables in most categories, indicating the presence of between-study heterogeneity. Exceptions were VAS value in the EQ-5D/HD category; age, index value, and VAS value in the EQ-5D/PD category; age in the TTO/PD category; and TTO value in the TTO/RTx category.
Random-effects-model means and 95% CIs for utilities are shown in Tables 2-4 and Figure 2 . In addition, P-values of the treatment modality comparisons are shown in Figure 2 . Quality of life was most extensively studied in HD patients, in comparison to the other treatment groups. The mean utilities of dialysis patients were statistically significantly lower than the mean utility of RTx patients, when comparing EQ-5D-index values (HD 0.56, 95% CI 0.49-0.62; PD 0.58, 95% CI 0.50-0.67; RTx 0.81, 95% CI 0.72-0.90). The mean TTO values of HD, PD, and RTx patients were not statistically significantly different, although the utility of HD patients tended to be lower than the value of PD and RTx patients. Random-effects-modelmeans for HD and PD patients were compared for TTO, EQ-5D-index, and EQ-VAS studies. For both EQ-5D-index and EQ-VAS values, the means of HD and PD patients were similar. For the TTO studies, No meta-analyses were performed because HD studies were too heterogeneous with respect to anchoring of the VAS and there were too few PD and RTx groups. HD, hemodialysis; n, sample size; N/A, not available; PD, peritoneal dialysis; RTx, renal transplantation; SD, standard deviation;VAS,Visual Analog Scale.
mean quality of life was not significantly different, although it tended to be higher among PD patients (0.73, 95% CI 0.61-0.85) than among HD patients (0.61, 95% CI 0.54-0.68).
Means for age and sex computed using randomeffects models are also shown in Table 2 -4. For EQ-5D studies, mean age was computed for all three treatment modalities and RTx patients were significantly younger 
Discussion
From this systematic review and meta-analysis, we conclude that the comparisons of utilities of the alternative forms of RRT resulted in mostly nonsignificant differences, although quality of life tended to be highest for RTx and lowest for HD patients. For the EQ-5D utilities, RTx patients did have significantly higher quality of life than dialysis patients. There was no statistically significant difference in utilities between HD and PD patients, although when measured with the TTO, PD patients tended to have a higher quality of life. Among the alternative forms of RRT, utilities were most frequently studied in HD patients. A superior quality of life for RTx compared to dialysis patients has been described previously in meta-analyses. Cameron et al. reported less emotional No meta-analysis was performed for the EQ-VAS value of RTx patients, because there were too few RTx groups. CI, confidence interval; EQ-5D, EuroQol-5D; HD, hemodialysis; n, sample size; N/A, not available; PD, peritoneal dialysis; REM, Random-effects model; RTx, renal transplantation; SD, standard deviation. distress and more psychological well-being for RTx patients compared to dialysis patients [10] . We found, in a meta-regression analysis of SF-36 scores among RRT patients, that dialysis patients had a lower quality of life than RTx patients, but that this difference was in part explained by differences in age and prevalence of diabetes [16] . In the present meta-analysis, we also found that RTx patients were younger, which might partly explain our findings. In studies that directly compared utilities of RTx and dialysis patients, however, RTx patients were found to have a higher quality of life, even when correcting for covariates known to influence quality of life such as age, sex, marital status, renal diagnosis, and morbidity [7, 9] . The EQ-5D-index values of the US general population were recently reported by Hanmer et al. [43] . Compared to these published values, dialysis patients have a markedly lower quality of life, whereas RTx patients have a comparable quality of life (i.e., general population values for females and males: 0.79 and 0.82 in the age group of 50-59 years; and 0.75 and 0.79 in the age group of 60-69 years).
In our study, we found few statistically significant differences between treatment groups. The lack of statistically significant differences might be explained by the wide CIs. These wide CIs, calculated with randomeffects models, reflect the incorporation of withinstudy as well as between-study variances. Variation between the studies existed, for example, in elicitation techniques, and patient populations. Heterogeneity in patient populations is due to numerous reasons: several demographic and clinical variables are known to influence of quality of life. One might argue that studies showed too much variation to perform metaanalyses. With our analyses, however, we accounted for variation in different ways, depending on the type of variation. With respect to differences in elicitation techniques of the TTO and SG, studies showed that results are similar using an interviewer-based technique or an article-based technique [44, 45] . Therefore, combining results from studies using different elicitation techniques seems justified. As for variation in patient populations: because the aim of our study was to obtain summary estimates for adjustment of quality of life in economic evaluations that should be generalizable to the entire population, we feel that summarizing utility estimates over all patients included in our study is appropriate. This is in line with what has been suggested by Laird and Mosteller, which is if the purpose of the meta-analysis is to study a broad issue, then summarizing the information about that variation, using a random-effects model, is an important contribution [23] .
Several limitations to our study deserve mention. First, the reliability of meta-analyses always depends on the completeness of published studies and may therefore be subject to publication bias. As the studies included in our meta-analysis were mostly noncomparative, this bias should be relatively small. Second, the number of studies per category was small for most categories, especially for PD and RTx patients.
In addition, we would have wanted to make a recommendation as to which utility measure to choose for adjustment in economic analyses. Nevertheless, the number of studies that used more than one measurement method was too limited. from the societal perspective, general public values should be used because these represent aggregate values of people without specific interest in particular health states [46] . The Panel on CostEffectiveness in Health and Medicine also recommended the use of methods that allow patients' values of health profiles to be converted to utilities using a tariff based on utilities of the general public for the health profiles [47] , such as the EQ-5D index and the HUI. In our meta-analysis, we found that EQ-5D-index values were available in the literature for HD, PD, and RTx patients.
Although it is generally accepted that quality of life is an important parameter in economic analysis, the operationalization of the concept is still under debate. As has already been described in the 80s by Mulley, there are many pitfalls in quality-of-life assessment [48] . Mulley argues that defining "health" is difficult and can be influenced by a large number of variables and that different disciplines--economy or psychology--hold different views of how to establish health outcomes. Most importantly, Mulley discusses how utility measurement has shown incongruities. Not only do the results vary by utility measure, but also the timing of measurement is important because utility changes over the course of life, and shows a response shift during disease progression in chronic diseases. Therefore, utility assessment should be tailored to the purpose of the measurement. For economic analyses, the goal is to maximize quality-adjusted life-years and therefore, to establish a consensus view of the preference for the various health outcomes. Thus, aggregating across ratings from different populations seems justified.
In conclusion, our meta-analysis of utilities of patients on RRT shows that RTx patients tended to have a higher quality of life compared to dialysis patients, but are also younger. There was no statistically significant difference between HD and PD patients' mean utilities. The results from this metaanalysis can be used to adjust life expectancy for quality of life in cost-effectiveness studies of programs for ESRD patients.
